Skip to main content
Journal cover image

Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neck.

Publication ,  Journal Article
Weiss, J; Gilbert, J; Deal, AM; Weissler, M; Hilliard, C; Chera, B; Murphy, B; Hackman, T; Liao, JJ; Grilley Olson, J; Hayes, DN
Published in: Oral Oncol
September 2018

BACKGROUND: Although induction studies of TPF in SCCHN have not improved outcomes compared to chemoradiotherapy alone, phase II studies of weekly carboplatin (CbP), paclitaxel and cetuximab (C225) have shown promising results. Nano-albumin-paclitaxel (nab-paclitaxel) based chemotherapy has demonstrated a higher response rate (RR) than solvent-based paclitaxel in squamous cell carcinoma of the lung with favorable toxicity. MATERIALS AND METHODS: Patients with treatment naïve SCCHN of any site with ≥N2b disease or that was unresectable by strict criteria were eligible. Patients were treated with nab-paclitaxel 100 mg/m2, CbP area under the curve (AUC) 2 and C225 400 mg/m2 week 1 then 250 mg/m2 for six weeks, followed by standard of care chemoradiotherapy (CRT). The primary endpoint was clinical response rate to induction therapy as defined by RECIST version 1.1. Secondary measures included toxicity, progression-free survival, overall survival and quality of life as measured by FACT-HN. RESULTS: 38 eligible subjects were treated. Primary sites were: oropharynx (OPX) (25), larynx (3) oral cavity (OC) (9), hypopharynx (1). The most common grade 3 or 4 toxicity during induction was acneiform rash (26%) followed by neutropenia (16%). RR was 76.3%. Median PFS and OS have not been reached (median follow-up of 3.3 years); they were superior in patients with response. CONCLUSIONS: The combination of nab-paclitaxel, CbP and C225 is feasible, tolerable and active against locally advanced SCCHN.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Oral Oncol

DOI

EISSN

1879-0593

Publication Date

September 2018

Volume

84

Start / End Page

46 / 51

Location

England

Related Subject Headings

  • Treatment Outcome
  • Squamous Cell Carcinoma of Head and Neck
  • Radiotherapy, Intensity-Modulated
  • Progression-Free Survival
  • Paclitaxel
  • Oncology & Carcinogenesis
  • Neutropenia
  • Neoplasm Staging
  • Neoadjuvant Therapy
  • Middle Aged
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Weiss, J., Gilbert, J., Deal, A. M., Weissler, M., Hilliard, C., Chera, B., … Hayes, D. N. (2018). Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neck. Oral Oncol, 84, 46–51. https://doi.org/10.1016/j.oraloncology.2018.06.028
Weiss, Jared, Jill Gilbert, Allison Mary Deal, Mark Weissler, Chris Hilliard, Bhishamjit Chera, Barbara Murphy, et al. “Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neck.Oral Oncol 84 (September 2018): 46–51. https://doi.org/10.1016/j.oraloncology.2018.06.028.
Weiss, Jared, et al. “Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neck.Oral Oncol, vol. 84, Sept. 2018, pp. 46–51. Pubmed, doi:10.1016/j.oraloncology.2018.06.028.
Weiss J, Gilbert J, Deal AM, Weissler M, Hilliard C, Chera B, Murphy B, Hackman T, Liao JJ, Grilley Olson J, Hayes DN. Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neck. Oral Oncol. 2018 Sep;84:46–51.
Journal cover image

Published In

Oral Oncol

DOI

EISSN

1879-0593

Publication Date

September 2018

Volume

84

Start / End Page

46 / 51

Location

England

Related Subject Headings

  • Treatment Outcome
  • Squamous Cell Carcinoma of Head and Neck
  • Radiotherapy, Intensity-Modulated
  • Progression-Free Survival
  • Paclitaxel
  • Oncology & Carcinogenesis
  • Neutropenia
  • Neoplasm Staging
  • Neoadjuvant Therapy
  • Middle Aged